Presenilin1 (PSEN1) gene is the most common known genetic cause of early-onset familial Alzheimer’s disease. We describe an Italian family with the known p.Ala260Gly mutation in PSEN1 gene. The presence of an asymptomatic 64-year-old male carrying the mutation provides evidence of a possible incomplete penetrance leading to a wider range of age at onset. In order to evaluate whether or not epigenetic modifications could contribute to the phenotypic heterogeneity, we assessed global DNA methylation levels which resulted significantly higher in the three females than in their presymptomatic brother. The study suggests that DNA methylation can contribute to slowing down or possibly protecting from the manifestation of symptoms even in monogenic diseases, emphasizing the great complexity of familial Alzheimer’s disease.

Incomplete penetrance in familial Alzheimer’s disease with PSEN1 Ala260Gly mutation / Piaceri I.; Chiari A.; Galli C.; Bagnoli S.; Ferrari C.; Saavedra S.T.; Molinari M.A.; Vinceti G.; Sorbi S.; Nacmias B.. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-3478. - STAMPA. - 41:(2020), pp. 2263-2266-2266. [10.1007/s10072-020-04421-6]

Incomplete penetrance in familial Alzheimer’s disease with PSEN1 Ala260Gly mutation

Piaceri I.;Bagnoli S.;Ferrari C.;Sorbi S.;Nacmias B.
2020

Abstract

Presenilin1 (PSEN1) gene is the most common known genetic cause of early-onset familial Alzheimer’s disease. We describe an Italian family with the known p.Ala260Gly mutation in PSEN1 gene. The presence of an asymptomatic 64-year-old male carrying the mutation provides evidence of a possible incomplete penetrance leading to a wider range of age at onset. In order to evaluate whether or not epigenetic modifications could contribute to the phenotypic heterogeneity, we assessed global DNA methylation levels which resulted significantly higher in the three females than in their presymptomatic brother. The study suggests that DNA methylation can contribute to slowing down or possibly protecting from the manifestation of symptoms even in monogenic diseases, emphasizing the great complexity of familial Alzheimer’s disease.
2020
41
2263-2266
2266
Goal 3: Good health and well-being for people
Piaceri I.; Chiari A.; Galli C.; Bagnoli S.; Ferrari C.; Saavedra S.T.; Molinari M.A.; Vinceti G.; Sorbi S.; Nacmias B.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1204122
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact